0.97 USD
▼-0.06-0.18%
盘后 0.99 +1.99%
2026-08-03
市值
$125.12M
市盈率
—
EPS
-0.16
股息率
—
52 周区间
0.87 – 2.53
成交量
577.80K
Beta
0.46
目标价
—
52W 低 0.8752W 高 2.53
价格走势
公司简介
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer’s disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune an...